enables wider use, and maintains NHSN to obtain scientifically valid clinical performance indices and benchmarks that promote healthcare quality and value at the facility, state, and national levels; (6) conducts applied research to identify and develop innovative methods to detect and monitor HAI and antimicrobial resistance; (7) conducts special studies and provides national estimates of targeted, healthcare-associated adverse events, antimicrobial use and resistance patterns, and the extent to which prevention and control safeguards are in use to protect at-risk patients across the spectrum of healthcare delivery sites; (8) uses NHSN and other data sources to conduct special studies and provide national estimates of targeted occupational illnesses and injuries among healthcare workers and the extent to which preventive safeguards are in use across the spectrum of healthcare delivery sites; and (9) leads CDC’s national adverse drug events surveillance activities and seeks to translate population-based surveillance data into evidence-based policies and targeted, innovative and collaborative interventions.

**Immunization Safety Office (CVLDE).** (1) Assesses the safety of new and currently available vaccines received by children, adolescents, adults; (2) coordinates vaccine safety activities at CDC; (3) conducts public health surveillance to identify adverse events following immunization; (4) in collaboration with the Food and Drug Administration, coordinates and maintains the Vaccine Adverse Event Reporting System, a national reporting system that serves as an early-warning system to detect medical problems that may be related to vaccines; (5) coordinates and maintains the Vaccine Safety Datalink, a collaborative effort with managed care organizations, to assess adverse events following immunization; (6) administers the Clinical Immunization Safety Assessment network, a national network of medical research centers with expertise in immunization safety conducting clinical research on immunization-associated health risks; (7) participates in the Brighton Collaboration, an international collaboration of scientists from around the world working to develop, evaluate, and disseminate globally accepted standard case definitions for adverse events following immunization and guidelines for collection, analysis, and presentation of vaccine safety data; and (8) works with other federal agencies, state governments, and other public and private organizations to assess and promote the safety of vaccines.

**James D. Seligman,**
**Acting Chief Operating Officer, Centers for Disease Control and Prevention.**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**National Institute of Neurological Disorders and Stroke; Notice of Meeting**

Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of a meeting of the Muscular Dystrophy Coordinating Committee (MDCC).

The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should inform the Contact Person listed below in advance of the meeting.

**Name of Committee:** Muscular Dystrophy Coordinating Committee.

**Date:** April 20, 2011.

**Time:** 8 a.m. to 4:30 p.m.

**Agenda:**

- The 2011 meeting of the MDCC will review Federal agency activities in the muscular dystrophies, brief participants on the NIH grant database, NIH RePORTER, discuss therapy development resources at the NIH, and review joint NIH/FDA activities and initiatives in rare diseases. The MDCC will also discuss new opportunities in therapy development based upon a representative example of a new mechanistic finding and the lessons learned in current drug development programs. A panel will review and discuss the challenges of conducting clinical trials in the muscular dystrophies.

**An agenda will be posted prior to the meeting on the MDCC Web site:** [http://www.ninds.nih.gov/find_people/groups/mdcc/index.htm](http://www.ninds.nih.gov/find_people/groups/mdcc/index.htm).

**Place:** Hilton Rockville Hotel & Executive Meeting Center, 1750 Rockville Pike, Rockville, Maryland 20852–1699.

**Contact Person:** John D. Porter, PhD, Executive Secretary, Muscular Dystrophy Coordinating Committee, National Institute of Neurological Disorders and Stroke, NIH, 6001 Executive Boulevard, NSC 2172, Bethesda, MD 20892, (301) 496–5739, porterj@ninds.nih.gov.

Any interested person may file written comments with the committee by forwarding their statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

(Catalogue of Federal Domestic Assistance Program Nos. 93.853, Clinical Research Related to Neurological Disorders; 93.854, Biological Basis Research in the Neurosciences, National Institutes of Health, HHS)

**Dated:** March 11, 2011.

**Jennifer S. Spaeth,**
**Director, Office of Federal Advisory Committee Policy.**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**Open Meeting Notice**

Notice is hereby given that the National Institutes of Health (NIH), Department of Health and Human Services, will hold a scientific workshop.

**Title:** “State of the Knowledge Workshop on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Research”.

**Dates:** April 7–8, 2011.

**Time:** 8 a.m. to 5 p.m.

**Place:** Building 31, Conference Rooms 6C8/9/10, NIH campus, Bethesda, Maryland.

**Purpose of the Meeting:** This workshop will bring together subject matter experts who will discuss multiple aspects of ME/CFS, including epidemiology, etiology, pathophysiology, diagnosis, and treatment. The workshop panelists will identify gaps in knowledge and opportunities for advancing biomedical research.

This workshop is open to the public. Please note that attendance is limited. We encourage registration for those attending in person (see Web address below). For those unable to attend, the workshop will be available via NIH VideoCasting ([http://videocast.nih.gov/](http://videocast.nih.gov/)) both during and after the event.

Individuals with disabilities who need reasonable accommodation should indicate their needs on registration or contact Infinity Conference Group by telephone at 703–925–9455, ext. 0, or e-mail at icg@infinityconferences.com.

For more information including an agenda, registration, and visitor information, please visit the workshop Web site: [https://www.infinityconferences.com/InfiniBase/Templates/157537/Index.htm](https://www.infinityconferences.com/InfiniBase/Templates/157537/Index.htm).

**Contact Person:** Dennis Mangan, PhD; Chair, Trans-NIH ME/CFS Research Working Group, Office of Research on